Evidence map›Paper›PMID 39570507›Full record

ArticleBiochemical genetics2025

Distribution of High-Risk Human Papillomavirus in Self-Collected Cervicalvaginal Samples from the General Malian Population.

Bakarou Kamate, Yaya Kassogue, Brehima Diakite, Ban Traore, Kadidiatou Cisse, Fousseyni Diarra, Oumar Kassogue, Modibo Diarra, Aissata Coulibaly, Bourama Coulibaly and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Bakarou KamateCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Yaya KassogueCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali. kassoy2@yahoo.fr.
Brehima DiakiteCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Ban TraoreCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Kadidiatou CisseCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Fousseyni DiarraCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Oumar KassogueCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Modibo DiarraCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Aissata CoulibalyCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Bourama CoulibalyCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Aminata MaigaCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Madani LyCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Hama DialloFaculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Sidi Boula SissokoCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Adama Seydou SissokoCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Cheick Bougadari TraoreCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Ibrahima TegueteCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Sekou BahCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Guimogo DoloCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
Demirkan Besim GurselDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Jane HollDepartment of Neurology, Northwestern University, Chicago, IL, 60637, USA.
Lifang HouInstitute for Global Health, Northwestern University, Chicago, IL, 60611, USA.
Mamoudou MaigaCentre of Research and Training On Molecular Pathologies, University Hospital of Point G, Bamako, Mali.

Funding

West Africa Self-Sampling HPV Based Cervical Cancer Control Program (WA-SS-HCCP) for WLWHA: Barriers, challenges, and needsU01CA275129 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI JANE Louise HOLL, Lifang Hou · 2022 to 2026
$3.2M
NCI NIH HHS U01 CA275129
6 · The paper itself

Abstract

Cervical cancer (CC) remains a real public health problem in low- and middle-income countries, where technical resources and competent personnel are insufficient. Persistent cervix infection by high-risk human papillomavirus (Hr-HPV) is the main cause of CC development. In the current study, we examined the distribution of Hr-HPV in the general healthy Malian population using cervicovaginal self- sampling. A total of 354 women were recruited, with a median age of 34 ± 11.37 years, IQR (27-43). We found that 100% of participants agreed to self-sample at the health center. For result announcement 99.2% expressed their preference to be contacted by cell phone. Furthermore, 100% of study participants showed their willingness to undergo confirmatory CC test in case of Hr-HPV test proved positive, and to receive treatment in the event of the presence of cervical lesions. The overall prevalence of Hr-HPV was 21.2% (95% CI: 17-25.8). HPV31/35/33/52/58 with 11.9% (95% CI: 8.7-15.7) and HPV39/68/56/66 with 5.9% (95% CI: 3.7-8.9) were the most common Hr-HPV subtypes. We noted that Hr-HPV genotypes were more prevalent among women under 25 years, 36.1% (N = 61). In addition, the distribution of Hr-HPV was statistically associated with age, W = 12,374, p = 0.015. Our data showed that 25.3% (N = 19) of Hr-HPV-positive women were tested positive by VIA/VILI. Among the 19 VIA/VILI-positive women, histological examination showed that 4 were CIN1, 4 were CIN2, and 2 were CIN3 grades. In addition, the median age of participants with CIN2 and CIN3 was statistically higher than the median of those with CIN1 grade, 25 years IQR (21-26.75) versus 50 years, IQR (40.25-55), W = 24, p = 0.009. In sum, end-users are very satisfied with the cervicovaginal self-sampling device for identifying HR-HPV genotypes as part of CC screening. In addition, it enables hospital practitioners to take the necessary action after triaging women according to their HR-HPV genotype.

Indexed as

Cervix UteriPapillomaviridaePapillomavirus InfectionsUterine Cervical NeoplasmsVaginaAdultFemaleHuman Papillomavirus VirusesHumansMiddle AgedCC screeningGenotypesHr-HPVMaliSelf-sampling

Identifiers

PMID39570507

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.